Table 3.

Treatment adverse events reported in VE-BASKET, ROAR and COMBI-AD trial.

VE-BASKET TRIAL (vemurafenib)			NCT01227889 (dabrafenib)			ROAR TRIAL (dabrafenib + trametinib)			COMBI-AD TRIAL (dabrafenib + trametinib)
ADVERSE EVENT	ALL GRADES	GRADE 3-4	ADVERSE EVENT	ALL GRADES	GRADE 3-4	ADVERSE EVENT	ALL GRADES	GRADE 3-4	ADVERSE EVENT	ALL GRADES	GRADE 3-4
arthralgia	67%	/	pyrexia	8%	3%	fatigue	41%	41%	pyrexia	63%	5%
palmar-plantar erythrodysesthesia	38%	/	arthralgia	19%	1%	headache	38%	38%	fatigue	47%	4%
photosensitivity reaction	38%	/	fatigue	18%	1%	nausea	32%	32%	nausea	40%	1%
fatigue	29%	4%	squamous carcinoma keratoacanthoma	12%	4%	pyrexia	31%	31%	headache	39%	1%
pruritus	29%		palmar-plantar hyperkeratosis	16%	2%	neutropenia	10%	10%	chills	37%	1%
rash maculopapular	29%	13%	hyperkeratosis	12%	<1%	anaemia	22%	22%	diarrhea	33%	1%
folliculitis	25%	/	keratoacanthoma	12%	4%	AST/ALT elevation	17%	17%	vomiting	28%	1%
hyperkeratosis	25%	/	headache	5%	/	chills	14%	14%	arthralgia	28%	1%
keratosis pilaris	25%	/	nausea	1%	1%	/	12%	12%	rash	24%	/
headache	25%	/	vomiting	1%	/	ejection fraction decrease	10%	10%	cough	17%	/
diarrhoea	21%	/	neutropenia	1%	1%	dermatitis acneiform	10%	10%	hypertension	11%	6%
nausea	21%	/	diarrhoea	/	/	hypertension	3%	3%	elevated ATS/ALT	15%	4%
decreased appetite	21%	/	cardiac	/	/	diarrhoea	14%	14%	dermatitis acneiform	12%	/